Elsevier

Gynecologic Oncology

Volume 71, Issue 2, November 1998, Pages 230-239
Gynecologic Oncology

Regular Article
Prognostic Factors in Extraovarian Primary Peritoneal Carcinoma

https://doi.org/10.1006/gyno.1998.5090Get rights and content

Abstract

Objective.To determine the pathological, clinical, and therapeutic factors which had prognostic significance in women with extraovarian primary peritoneal carcinoma (EOPPC).

Methods.A retrospective, clinicopathologic study was conducted of 75 women diagnosed with EOPPC. Diagnosis and assessment of prognostic pathological factors were based on the Gynecologic Oncology Group (GOG) criteria. Univariate and multivariate analyses were used to assess the following factors for their effect on overall survival: age, parity, presenting symptoms and signs, ascites, CA 125 level, history of oophorectomy, maximum ovarian dimension, histologic type, architectural and nuclear grades, number of mitosis and psammoma bodies, depth of ovarian invasion, estrogen and progesterone receptors (positive, negative), p53 overexpression (present, absent), performance status (GOG criteria), stage (FIGO criteria for ovarian cancer), debulking surgery (optimal versus suboptimal), first-line chemotherapy (platin-based without paclitaxel versus platin/paclitaxel), secondary cytoreduction, and second-line chemotherapy (paclitaxel-based versus no paclitaxel).

Results.The median overall survival of all patients was 23.5 months (95% CI 18.6, 39.8 months). The 5-year survival was 26.5% (SE 6.7%). p53 overexpression and estrogen and progesterone receptor positivity were demonstrated in 42.4, 50.0, and 6.3%, respectively. In univariate analysis, performance status, primary debulking surgery, stage, and age were significant on overall survival (P< 0.001, <0.001, 0.004, and 0.012, respectively). In multivariate analysis, only performance status (P< 0.001) and primary debulking surgery (P= 0.03) were independent prognostic factors.

Conclusions.Overall survival in women with EOPPC is affected significantly by performance status and primary debulking surgery as independent variables. To improve survival, efforts should be made to achieve optimal tumor cytoreduction at primary surgery.

References (41)

  • JP Geisler et al.

    Estrogen and progesterone receptor status as prognostic indicators in patients with optimally cytoreduced stage IIIC serous cystadenocarcinoma of the ovary

    Gynecol Oncol

    (1996)
  • TH Parmely et al.

    The ovarian mesothelioma

    Am J Obstet Gynecol

    (1974)
  • L Resta et al.

    Multifocal extraovarian serous carcinoma: a histochemical and immunohistochemical study

    Eur J Gynecol Oncol

    (1988)
  • S Gooneratne et al.

    Serous surface papillary carcinoma of the ovary: a clinicopathologic study of 16 cases

    Int J Gynecol Pathol

    (1981)
  • SE Mills et al.

    Serous surface papillary carcinoma: a clinicopathologic study of 10 cases and comparison with stage III–IV ovarian serous carcinoma

    Am J Surg Pathol

    (1988)
  • CZ August et al.

    Multiple focal extraovarian serous carcinoma

    Int J Gynecol Pathol

    (1985)
  • LD Kowalski et al.

    A case-matched comparison of extraovarian versus primary ovarian adenocarcinoma

    Cancer

    (1997)
  • JC Dalrymple et al.

    Extraovarian peritoneal serous papillary carcinoma: a clinicopathologic study of 31 cases

    Cancer

    (1989)
  • GL Fromm et al.

    Papillary serous carcinoma of the peritoneum

    Obstet Gynecol

    (1990)
  • DT Ransom et al.

    Papillary serous adenocarcinoma of the peritoneum

    Cancer

    (1990)
  • Cited by (76)

    • Primary peritoneal serous carcinoma: a primer for radiologists

      2022, Clinical Imaging
      Citation Excerpt :

      PPSC has been demonstrated to have a poor prognosis similar to or even worse than that of advanced serous ovarian carcinoma.5 Median overall survival is typically reported in the range of 21 to 23.5 months, though this value is prone to large fluctuations across studies due to small sample sizes.6–8 Treatment of PPSC typically mirrors that of stage III/IV ovarian carcinoma, which includes surgical debulking and chemotherapy, as similar response rates between the two have been demonstrated.9,10

    • Diseases of the Peritoneum

      2020, Gynecologic Pathology, Second Edition
    • Clinico-pathological outcomes after total parietal peritonectomy, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in advanced serous papillary peritoneal carcinoma submitted to neoadjuvant systemic chemotherapy- largest single institute experience

      2019, European Journal of Surgical Oncology
      Citation Excerpt :

      Diagnosing SPPC is a challenge as, most patients, present with diffuse peritoneal spread without any apparent disease in the ovaries. This is seen in 10–20% cases wherein the diagnosis is SPPC and not epithelial ovarian carcinoma (EOC) [3–5]. In the absence of established standard treatment, serous papillary peritoneal carcinoma patients have been managed with cytoreductive/debulking surgery and platinum and taxane based chemotherapy, similar to epithelial ovarian cancer [6,7].

    • Epithelial ovarian cancer

      2018, Clinical Gynecologic Oncology
    View all citing articles on Scopus

    Benda, J, AZaino, R

    1

    To whom correspondence and reprint requests should be addressed at present address: Gynecologic Oncology, University of Vermont, MCHV Campus, Shepardson 330, 111 Colchester Avenue, Burlington, VT 05401-1429. Fax: 802-656-2360. E-mail:[email protected].

    View full text